According to Ken Research Analysis, the Global Metabolomics Market was valued at ~US$ 1.5 billion in 2017. The availability of government and private funding for metabolomics research has driven the global metabolomics market’s rapid expansion. A significant emphasis is being placed on cutting-edge methods that can effectively detect and treat life-threatening diseases, such as cancer and cardiovascular disease, owing to the prevalence and mortality rate of such diseases.
It is estimated to be ~US$ 2.5 billion in 2022 and is expected to reach a market size of ~US$ 5 billion by 2028 growing at a CAGR of ~12% during 2022-2028.
For more information, Request A Free Sample Report
Key Growth Drivers
- Metabolomics offers a rising focus on innovative approaches with significant potential due to the rise in life-threatening diseases like cancer neurological conditions, and coronary heart disease, which has resulted in a surge in both government and private investments in the industry.
- Another factor promoting metabolomics market expansion is the combination of metabolomics and machine learning (ML). Nuclear Magnetic Resonance (NMR) and Multiple sclerosis (MS) data can be accurately interpreted with the use of machine learning (ML), which also automates employment, and complex processes.
- A variety of heterogeneous data is generated by metabolomics techniques, and interpreting such data can be difficult and complex. Any analytical method cannot be used to analyze the data due to the chemical diversity of small molecule metabolites. The prosperity of the market as a whole is being impeded by all of such factors.
- The metabolomics market has a potential impact from COVID-19. As a result of the utilization of metabolomics in research to understand COVID-19 diseases.
Key Trends by Market Segment
By Product and Services – The Metabolomics Instrument by Product and Services dominated the market in 2021, due to the extensive utilization of market products in research activities around the world in the disciplines of medicine, nutraceuticals, and metabolomics.
- The growth is attributed to the rapid acceptance of metabolomics and smooth technological operations, which leads to increased workflow efficiency, precision, dependability, and data processing.
- During the forecast period, factors such as the technical improvements in analytical instruments in terms of miniaturization, automation, and computerization, and the improvement of healthcare infrastructure in developing countries for effective illness detection and treatment are anticipated to drive the growth of the segment.
For more information, Request A Free Sample Report
By Indication – The Cancer segment accounted for the highest market share in 2021, owing to the rise in cancer incidence around the globe and the expansion of oncological research projects.
- According to World Health Organization (WHO), in February 2022 stated that Cancer is the leading cause of death throughout the world, accounting for nearly 10 million deaths in 2020, or nearly one in each six.
- According to the American Cancer Society, in 2021, there will be an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the United States
By Application – Biomarker Discovery accounted for the highest market share in 2021 owing to the worldwide increase in the prevalence of chronic diseases such as Cancer, Chronic Obstructive Pulmonary Disease (COPD), and Arthritis.
- The market’s bigger contribution to the discovery of new biomarkers is also driven by extensive oncological research with a preference for the study of such markers and their application in the treatment of cancer.
- Metabolic biomarkers are rapidly being utilized to assess patients’ pathophysiological health conditions. Metabolomics has evolved in recent years into a crucial tool for identifying biomarkers as a result of major technological advancements.
By Geography: North America accounted for the largest market share among all regions in 2021, owing to the presence of major Metabolomics studies and testing organizations like Agilent Technologies, Inc., Danaher., Waters Corporation, Bruker, and many more.
- The region’s substantial proportion can be linked to increasing biomedical research in the United States and rising preclinical operations by Contract research organizations (CROs) and pharmaceutical companies in the region.
- According to the Centers for Disease Control and Prevention (CDC), in January 2022, 6 out of 10 adults in the United States have a chronic disease, and 4 out of 10 persons have more than one or two. The high prevalence of chronic diseases necessitates the development of novel, cutting-edge therapies, increasing the use of metabolomics and fostering business expansion.
Competitive Landscape
The Global Metabolomics Market is highly competitive with ~200 players which include globally diversified players, regional players as well as a large number of country-niche players each with their niche in Metabolomics research and testing. Large global players constitute ~20% of competitors, while country niche players represent the largest number of competitors. New drug discoveries are increasingly in demand. The demand for metabolomics is rising since it is used to test prospective biomarkers (certain cells, chemicals, genes, gene products, enzymes, or hormones) to assess the responsiveness of cancer therapy and enable early detection. The market is expanding as a result of strategic actions such as partnerships, collaborations, mergers, acquisitions, new product launches, and the rising demand for cutting-edge technologies. Some of the major players in the market include Agilent Technologies, Inc., Danaher, Shimadzu Corporation, Waters Corporation, Bruker, Human Metabolome Technologies Inc., Thermo Fisher Scientific, LECO Corporation, Metabolon INC, PerkinElmer Inc., and others.
Recent Developments Related to Major Players
- In March 2020, Danaher Corporation announced that it had successfully acquired the Life Sciences section of General Electric Company’s Biopharma business. The company will be a stand-alone operating company within Danaher’s Life Sciences division and will be a part of Danaher under the name Cytiva.
- In June 2021, Bruker Corporation announced the launch of two new Tim stop instruments: Next-gen timsTOF Pro 2 with Unprecedented Proteomic Depth and tims TOF SCP for Unbiased Single Cell 4D-Proteomics.
Conclusion
The Global Metabolomics Market is anticipated to grow significantly during the projected period (2022-2028) owing to the growing availability of government and corporate funding for metabolomics research, increasing R&D expenditure in the pharmaceutical and biopharmaceutical industry, and ongoing improvements in metabolomics technologies driving the expansion of the global metabolomics market during the anticipated period. Though the market is competitive with ~200 participants, country-niche players control the dominant share and regional players also hold a significant share.
Ken Research has recently published report titled Global Metabolomics Market Size, Segments, Outlook, and Revenue Forecast 2022-2028The Global Metabolomics Market is segmented into By Products and Services, Indications, and Applications. In addition, the report also covers market size and forecasts for the four regions. The revenue used to size and forecast the market for each segment is US$ Billion
Market Taxonomy
| By Product and Services |
|
| By Indication |
|
| By Application |
|
| By Geography |
Asia Pacific (China, India, Japan, South Korea, Australia, and Rest of Asia Pacific)
|
| Key Players |
|
For more insights on the market intelligence, refer to the link below:-
Follow Us
LinkedIn | Instagram | Facebook | Twitter | YouTube
